Lilia AI

Lilia AI is building novel, first-in-world agentic AI software for diagnosing brain aneurysms on CT scans, integrating directly into existing radiology workflows via EMR/PACS. The platform leverages a modular, autonomous multi-agent architecture — including specialized inference agents, real-time learning agents, and bias detection agents — to deliver superior detection accuracy, automated radiology report generation via LLMs, and urgent case triage, regulated by the FDA as a Software as a Medical Device (SaMD). Lilia AI is pursuing FDA 510(k) clearance and targets hospitals, health systems, physician practices, and outpatient imaging centers with a SaaS plus insurance reimbursement revenue model. The company has already filed patents, generated early revenue, signed its first MRR contract, and been accepted into NVIDIA Inception, Creative Destruction Lab, and Rice Launchpad.

1 in 50 Americans (6.7M people) have an unruptured brain aneurysm, and a rupture occurs every 18 minutes, often resulting in death or permanent disability. Diagnosing brain aneurysms is error-prone and slow, with a high potential for missed diagnoses, compounded by a national shortage of radiologists against a rising volume of imaging scans.

Lilia AI's patented agentic AI software diagnoses brain aneurysms on CT scans 50x faster than a human radiologist with >90% accuracy, auto-generates radiology reports using LLMs, and integrates directly into EMR/PACS systems for real-time triage. Its modular multi-agent architecture outperforms first-generation competitors (Viz.ai, Aidoc, RapidAI) on edge-case detection, workflow adaptability, and continuous learning from clinician feedback.

Lilia AI has raised its first investor funding, filed two patents (Patent #1 issued by USPTO), generated $57,750 in custom software development revenue, signed a $3,000 MRR contract, secured a customer LOI, established partnerships with Integrated Imaging and Texas A&M School of Engineering Medicine, and was accepted into NVIDIA Inception, Creative Destruction Lab, and Rice Launchpad. The company is now raising $2M to execute an 18-month roadmap to FDA clearance.